Archemix

closed

Archemix, a biotechnology company, develops and commercializes aptamer therapeutics for the treatment of chronic and acute diseases.

Launch date

2000

Employees

Market cap

Enterprise valuation

San Francisco California (HQ)

Date	Investors	Amount	Round
-	Rho Canada Ventures	N/A	-
Aug 2002	Atlas Venture Prospect Venture Partners POSCO BioVentures SV Health Investors MDS Capital U.S. Trust & 1 more	$51.8m	Series A
Apr 2004	Highland Capital Partners Atlas Venture Prospect Venture Partners POSCO BioVentures Rho Ventures MDS Capital U.S. Trust Care Capital	$50.0m	Series B
Total Funding		€92.5m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Archemix